1. Ramipril

7. Pharmacokinetics (Absorption, Distribution, Metabolism, Excretion): Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.

16a. Renal Considerations: Renal: Explicitly renal-function dependent! Ramiprilat is renally cleared: if CrCl 20–50 mL/min, initiate at 1.25 mg OD (max 5 mg/day); if CrCl <20 mL/min, initiate at 1.25 mg OD and do not exceed 2.5 mg/day. Acceptable creatinine rise up to 20–30% after initiation stabilises intraglomerular pressure; if >30% rise, withhold and evaluate for renal artery stenosis. Hepatic: Impaired esterase conversion to ramiprilat; initiate at 1.25 mg OD under close monitoring (max 2.5 mg/day).

16b. Hepatic Considerations: Renal: Explicitly renal-function dependent! Ramiprilat is renally cleared: if CrCl 20–50 mL/min, initiate at 1.25 mg OD (max 5 mg/day); if CrCl <20 mL/min, initiate at 1.25 mg OD and do not exceed 2.5 mg/day. Acceptable creatinine rise up to 20–30% after initiation stabilises intraglomerular pressure; if >30% rise, withhold and evaluate for renal artery stenosis. Hepatic: Impaired esterase conversion to ramiprilat; initiate at 1.25 mg OD under close monitoring (max 2.5 mg/day).

• Persistent dry, non-productive hacking cough (5–20% of Indian patients, due to bradykinin and substance P accumulation), dizziness, postural lightheadedness, fatigue, metallic taste.
• Life-threatening angioedema (swelling of lips, tongue, pharynx, larynx—medical emergency), severe hyperkalaemia (K+ >5.5 mEq/L), acute renal failure, rare neutropenia/agranulocytosis.

• Sacubitril/valsartan within 36 hours (severe angioedema risk)
• Co-administration with mTOR inhibitors or DPP-4 inhibitors (vildagliptin/sitagliptin) slightly increases angioedema risk
• Potassium-sparing diuretics, K+ supplements, and cotrimoxazole (trimethoprim) cause severe hyperkalaemia
• NSAIDs blunt BP control and precipitate acute kidney injury
• Increases lithium levels

15. Use in Special Populations (Pregnancy, Lactation, Paediatrics, Geriatrics): Evaluate maternal-foetal benefit-risk ratio, paediatric mg/kg ceiling, and geriatric renal function prior to prescribing.

17. Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

• Patient Counselling Checklist: Take the very first tablet while seated or at bedtime to avoid dizziness. Explain that a dry, tickly throat cough that does not respond to cough syrups is a known side effect—if it disturbs sleep, the doctor can easily switch it to an ARB (like telmisartan). Seek emergency care immediately if lip or tongue swelling occurs.
• Meal & Clock Timing Instruction: May be taken before, during, or after meals (food delays absorption rate slightly but does not reduce total bioavailability of ramiprilat). (Initial first dose preferably at bedtime (to prevent first-dose orthostatic syncope); subsequent maintenance doses in the morning or divided morning and evening.)
• Missed Dose Protocol: Take on the same calendar day if remembered earlier in the day; if close to the next scheduled dose, skip the missed dose and resume the regular schedule. Never double the dose.
• Geriatric Dispensing Pearl: Start at 1.25 mg once daily in elderly patients, especially those on furosemide/torsemide or with heart failure. Always enforce the 'Sick Day Rule': temporarily pause ramipril during acute gastroenteritis, vomiting, or severe fever with dehydration to prevent acute kidney injury.

Storage & Dispensing Notes: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Capsules / Tablets: 1.25 mg, 2.5 mg, 5 mg, 10 mg